HIGHMARK | HIGHMARK

Outpatient Medical Injectable
Intra-Articular Hyaluronan Injections
Request Form: Fax to 833-581-1861 (Medical Benefit Only)

Member Name:____

Member Date of Birth:____

Member ID (UMI): ____ ☐ Medicare ☐ Commercial*

Ordering/Attending Provider Name: _______________________________ NPI: ____________________

Ordering/Attending Provider Address:____

Office Contact: ______________________ Phone #:____________________ Fax #:____________________

Servicing Facility/Vendor Name: _______________________________ Facility NPI:____________________

Servicing Facility/Vendor Address:____

Requested Start Date of Service: ____________________ ICD10 Diagnosis Code(s): ____________________

☐ **Buy & Bill** ☐ **Drug Supplied by Specialty Pharmacy** *(Pharmacy Name: ____________________ NPI: ____________________)*

DRUG INFORMATION (*please select one*)

PREFERRED PRODUCTS

These products DO NOT require authorization

- ☐ **Euflexxa (J7323)**
- ☐ **Supartz (J7321)**
- ☐ **GelSyn-3 (J7328)**
- ☐ **Durolane (J7318)**

NON-PREFERRED**

☐ Synvisc (J7325)	☐ GenVisc 850 (J7320)
☐ Synvisc-One (J7325)	☐ Hymovis (J7322)
☐ Monovisc (J7327)	☐ Synojoynt (J7331)
☐ Gel One (J7326)	☐ Triluron (J7332)
☐ Hyalgan (J7321)	☐ Visco-3 (J7321)
☐ Orthovisc (J7324)	☐ TriVisc (J7329)

****A non-preferred product *may be considered medically necessary* if the member has experienced a documented drug therapy failure (after an adequate trial), intolerance, or contraindication to ALL preferred products.**

****Medicare members currently established on a non-preferred therapy are not required to try a preferred option**

****Please specify if the member has tried and failed the following:** *(Answer below)*

Euflexxa (J7323) ☐ **Yes (Date: ____________)** ☐ **No**
Supartz (J7321) ☐ **Yes (Date: ____________)** ☐ **No**
GelSyn-3 (J7328) ☐ **Yes (Date: ____________)** ☐ **No**
Durolane (J7318) ☐ **Yes (Date: ____________)** ☐ **No**

Please provide clinical rationale for requesting a non-preferred product for this member:

____

****Please verify member's eligibility and benefits through the health plan****

CLINICAL INFORMATION

Does the member have a diagnosis of symptomatic painful osteoarthritis of the knee with no evidence of inflammatory arthritis? ☐ YES ☐ NO

Has the member failed to respond adequately to **at least 3 months** of conservative therapy as defined by the following:

- Activity modification, participation in a home exercise program implemented by a physical therapist, protective weight bearing. ☐ YES ☐ NO
- Non-narcotic analgesics (e.g., acetaminophen, NSAIDS) at Food and Drug Administration (FDA) or compendia based recommended therapeutic doses for osteoarthritis of the knee for a period of time adequate to assess therapeutic benefit, topical external analgesic preparations including capsaicin cream applied to affected knee joint, topical anti-inflammatory preparations applied to affected knee joint.
  ☐ YES ☐ NO
- Intra-articular corticosteroid injections. ☐ YES ☐ NO

Is the member unable to tolerate conservative therapy due to adverse side effects **or** other medical conditions?
☐ YES ☐ NO

Can cause of pain be attributed to other forms of joint disease other than osteoarthritis? ☐ YES ☐ NO

Will the injections be performed by a licensed medical professional (e.g., MD, DO, PA or CRNP)? ☐ YES ☐ NO

Does the member have any contraindications to hyaluronan injections? ☐ YES explain: ________________ ☐ NO

☐ **New Start**	☐ **Request for Repeat Treatment**
	Date of last series: ____ Has the member and provider elected to continue conservative/non-surgical management of the osteoarthritis (no surgery planned within six (6) months of viscosupplementation therapy) ☐ YES ☐ NO Is there a documented reduction in the dose of analgesics or anti-inflammatory medications in the three (3) month period following the injection series (NOTE: not required if the member requires these medications for a comorbid medical condition in addition to knee osteoarthritis) ☐ YES ☐ NO Is there a documented significant improvement in pain and functional capacity of the knee joint. (ex: an improvement in an objective measurement of pain and/or functional status VAS, WOMAC Index, or other validated objective measure) ☐ YES ☐ NO

Please attach all pertinent clinical information

Attached:

☐ **YES** ☐ **NO**

The following entities, which serve the noted regions, are independent licensees of the Blue Cross Blue Shield Association: Western and Northeastern PA: Highmark Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Choice Company, Highmark Health Insurance Company, Highmark Coverage Advantage Inc., Highmark Benefits Group Inc., First Priority Health, First Priority Life or Highmark Senior Health Company. Central and Southeastern PA: Highmark Inc. d/b/a Highmark Blue Shield, Highmark Benefits Group Inc., Highmark Health Insurance Company, Highmark Choice Company or Highmark Senior Health Company. Delaware: Highmark BCBSD Inc. d/b/a Highmark Blue Cross Blue Shield. West Virginia: Highmark West Virginia Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Health Insurance Company or Highmark Senior Solutions Company. Western NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Cross Blue Shield. Northeastern NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Shield.

All references to “Highmark” in this document are references to the Highmark company that is providing the member’s health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.